Novacyt Group November 2017

Novacyt Group

 

£15,000,000

IPO on AIM London

 

 

November 2017

Angle October 2017

Angle

 

£15,000,000

Secondary Fundraise

 

 

October 2017

Angle October 2017

Angle

 

£3,700,000

Acquisition of certain assets of Axela

 

October 2017

Amryt Pharma September 2017

Amryt Pharma

 

€15,000,000

Secondary Fundraise

 

 

September 2017

Tissue Regenix July 2017

Tissue Regenix

 

£23,000,000

Acquisition of CellRight Technologies

 

July 2017

Tissue Regenix July 2017

Tissue Regenix

 

£40,000,000

Secondary Fundraise

 

 


July 2017

BioLineRx March 2017

BioLineRx

 

$6,000,000

Upfront consideration Acquisition of Agalimmune

 

March 2017

Arix Bioscience February 2017

Arix Bioscience

 

£100,000,000

IPO on London
Main Market

 

 

February 2017

Redx Pharma February 2017

Redx Pharma

 

£12,000,000

Secondary Fundraise

 

 


February 2017

Imugene October 2016

Imugene

 

$3,200,000

Secondary Fundraise

 

 


October 2016

Novogen October 2016

Novogen

 

Fairness opinion in

association with

acquisition

 


October 2016

Oxford BioMedica September 2016

Oxford BioMedica

 

£11,500,000

Secondary Fundraise

 

 


September 2016

Lombard Risk June 2016

Lombard Risk

 

£8,300,000

Secondary Fundraise

 

 


June 2016

Angle June 2016

Angle

 

£10,200,000

Secondary Fundraise

 

 


June 2016

Skyepharma May 2016

Skyepharma

 

Strategic advisory

project

 

 


May 2016

Juniper May 2016

Juniper

 

Strategic advisory

project

 

 


May 2016

Redx Pharma March 2016

Redx Pharma

 

£10,000,000

Secondary Fundraise

 

 


March 2016

Oxford BioMedica February 2016

Oxford BioMedica

 

£8,100,000

Secondary Fundraise

 

 


February 2016

Perceptive Bioscience February 2016

Perceptive Bioscience

 

£50,100,0000

Private Placement

 

 


February 2016

Mereo BioPharma July 2015

Mereo BioPharma

 

£76,500,0000

Private Placement

 

 


July 2015

Avacta July 2015

Avacta

 

£22,000,000

Secondary Fundraise

 

 


July 2015

Lombard Risk May 2015

Lombard Risk

 

£4,000,000

Secondary Fundraise

 

 


May 2015

Oxford BioMedica May 2015

Oxford BioMedica

 

$50,000,000

Debt facility arrangement

 

 


May 2015

Clinigen April 2015

Clinigen

£135,000,000

Secondary Fundraise in

association with £225m

acquisition of IDIS

 


April 2015

Newron Pharmaceuticals April 2015

Newron Pharmaceuticals

 

CHF 24,300,000

Secondary Fundraise

 

 


April 2015

OSE Pharma March 2015

OSE Pharma

 

€22,000,000

IPO on Euronext Paris

 

 


March 2015

Admedus March 2015

Admedus

 

AUD$28,000,000

Secondary Fundraise

 

 


March 2015

Ark Therapeutics February 2015

Ark Therapeutics

Disposal of all Trading
Assets, Reverse Takeover,
admission to trading on
Standard Segment of
Official List

March 2013 –

February 2015

Venture Life Group December 2014

Venture Life Group

 

£4,320,000

Secondary Fundraise

 

 


December 2014

BTG December 2014

BTG

£150,000,000

Secondary Fundraise in

association with

PneumRX acquisition

 


December 2014

Oxford BioMedica May 2014

Oxford BioMedica

 

£25,700,000

Secondary Fundraise

 

 


May 2014

Admedus May 2014

Admedus

 

AUD$18,300,000

Secondary Fundraise

 

 


May 2014

Newron Pharmaceuticals April 2014

Newron Pharmaceuticals

 

CHF 18,600,000

Secondary Fundraise

 

 


April 2014

Verona Pharma March 2014

Verona Pharma

 

£14,000,000

Secondary Fundraise

 

 


March 2014

Venture Life Group March 2014

Venture Life Group

£26,400,000

IPO on AIM London

and acquisition of

Biokosmes Srl

 


March 2014

Oxford BioMedica December 2013

Oxford BioMedica

 

£5,000,000

Secondary Fundraise

 

 


December 2013

BTG June 2013

BTG

£106,000,000

Secondary Fundraise in

association with EKOS &

TheraSphere acquisition

 


June 2013

Lombard Medical June 2013

Lombard Medical

 

£23,000,000

Secondary Fundraise

 

 


June 2013

Dysis Medical April 2013

Dysis Medical

 

£7,400,000

Private Placement

 

 


April 2013

Proximagen August 2012

Proximagen PLC

 

$554,700,000

Sale of company to
Upsher Smith

 

August 2012

Oxford BioMedica July 2012

Oxford BioMedica

 

£11,600,000

Secondary Fundraise

 

 


July 2012

London

WG Partners
85 Gresham Street
London
EC2V 7NQ

Sydney

WG Partners Pty Ltd.
Level 2 Unit 204
111 Harrington Street
Sydney
NSW 2000

Minneapolis

PO Box 653
Prior Lake
MN 55372
United States